COMPANY

Crestone

HQ: Boulder, CO source · crestonepharma.com ↗ · Mountain

Keywords: tuberculosis infectious disease small molecule bacterial infections infectious diseases Clostridioides Difficile Infection graft versus host disease CRS3123

Location: Boulder, CO · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)28NIH grants

Timeline

Apr 21, 2025 Trial start Phase 1: Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants source ↗
Jan 5, 2021 Trial start Phase 2: Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT04781387	Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection	Phase 2	Completed	Jan 5, 2021	Apr 16, 2024 (actual)
NCT06988423	Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants	Phase 1	Completed	Apr 21, 2025	Jun 4, 2025 (actual)

NIH awards 28

Annual award amounts. Total $67.3M.

2026 NIH contract (government contract; not a grant and not an investment round) 75N93019C00056-P00016-9999-1 FY2026: $1,350,620 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OSCHNER, URS; recipient as written: CRESTONE, INC., BOULDER, CO. Development source ↗
2026 NIH contract (government contract; not a grant and not an investment round) 75N93020C00020-P00014-9999-1 FY2026: $3,501,414 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OCHSNER, URS ARNOLD; recipient as written: CRESTONE, INC., BOULDER, CO. Devel source ↗
2025 NIH contract (government contract; not a grant and not an investment round) 75N93019C00056-P00013-9999-1 FY2025: $3,904,060 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OSCHNER, URS; recipient as written: CRESTONE, INC., BOULDER, CO. Development source ↗
2025 NIH contract (government contract; not a grant and not an investment round) 75N93020C00020-P00010-9999-1 FY2025: $1,580,854 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OCHSNER, URS ARNOLD; recipient as written: CRESTONE, INC., BOULDER, CO. Devel source ↗
2024 NIH contract (government contract; not a grant and not an investment round) 75N93019C00056-P00011-9999-1 FY2024: $4,595,632 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OSCHNER, URS; recipient as written: CRESTONE, INC., BOULDER, CO. Development source ↗
2024 NIH contract (government contract; not a grant and not an investment round) 75N93020C00020-P00009-9999-1 FY2024: $970,628 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OCHSNER, URS; recipient as written: CRESTONE, INC., BOULDER, CO. Development of source ↗
Aug 2, 2023 NIH award 1R43AI179346-01 FY2023: $295,763 awarded for that fiscal year; activity R43 (SBIR); PI MASON, CLIFFORD W; recipient as written: CRESTONE, INC., BOULDER, CO. A Novel Small Molecule Therapeutic for Acute Graf source ↗
2023 NIH contract (government contract; not a grant and not an investment round) 75N93019C00056-P00010-9999-1 FY2023: $3,511,044 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OCHSNER, URS; recipient as written: CRESTONE, INC., BOULDER, CO. Advanced Dev source ↗
2023 NIH contract (government contract; not a grant and not an investment round) 75N93020C00020-P00008-9999-1 FY2023: $2,665,864 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OCHSNER, URS; recipient as written: CRESTONE, INC., BOULDER, CO. Development source ↗
2022 NIH contract (government contract; not a grant and not an investment round) 75N93019C00056-P00008-9999-1 FY2022: $4,519,619 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OCHSNER, URS; recipient as written: CRESTONE, INC., BOULDER, CO. Advanced Dev source ↗
2022 NIH contract (government contract; not a grant and not an investment round) 75N93020C00020-P00004-9999-1 FY2022: $9,592,833 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OCHSNER, URS; recipient as written: CRESTONE, INC., BOULDER, CO. Development source ↗
2021 NIH contract (government contract; not a grant and not an investment round) 75N93019C00056-P00004-9999-1 FY2021: $850,507 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OCHSNER, URS; recipient as written: CRESTONE, INC., BOULDER, CO. Advanced Devel source ↗
Apr 15, 2020 NIH award 1R43AI149820-01A1 FY2020: $143,960 awarded for that fiscal year; activity R43 (SBIR); PI OCHSNER, URS ARNOLD; recipient as written: CRESTONE, INC., BOULDER, CO. Preclinical Evaluation of CRS3123 for the Tre source ↗
2020 NIH contract (government contract; not a grant and not an investment round) 75N93019C00056-P00002-9999-1 FY2020: $11,122,997 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OCHSNER, URS; recipient as written: CRESTONE, INC., BOULDER, CO. Advanced De source ↗
2020 NIH contract (government contract; not a grant and not an investment round) 75N93020C00020-0-9999-1 FY2020: $3,717,345 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OCHSNER, URS; recipient as written: CRESTONE, INC., BOULDER, CO. Development of Th source ↗
2019 NIH contract (government contract; not a grant and not an investment round) 75N93019C00056-0-9999-1 FY2019: $3,439,774 awarded for that fiscal year; activity N01 (OTHER_NIH); PI OCHSNER, URS; recipient as written: CRESTONE, INC., BOULDER, CO. Advanced Developm source ↗
2019 NIH contract (government contract; not a grant and not an investment round) 272201500012C-P00008-9999-1 FY2019: $81,740 awarded for that fiscal year; activity N01 (OTHER_NIH); PI THALE, JARVIS; recipient as written: CRESTONE, INC., BOULDER, CO. Optimizing Lead source ↗
2018 NIH contract (government contract; not a grant and not an investment round) 272201500012C-4-0-1 FY2018: $2,575,997 awarded for that fiscal year; activity N01 (OTHER_NIH); PI THALE, JARVIS; recipient as written: CRESTONE, INC., BOULDER, CO. Optimizing Lead Ther source ↗
Aug 17, 2016 NIH award 5R44GM110848-03 FY2016: $716,061 awarded for that fiscal year; activity R44 (SBIR); PI SUN, XICHENG; recipient as written: CRESTONE, INC., BOULDER, CO. Optimization and Lead Selection of Novel Antimycobacte source ↗
2016 NIH contract (government contract; not a grant and not an investment round) 272201500012C-1-0-1 FY2016: $1,507,181 awarded for that fiscal year; activity N01 (OTHER_NIH); PI THALE, JARVIS; recipient as written: CRESTONE, INC., BOULDER, CO. Optimizing Lead Ther source ↗
Sep 8, 2015 NIH award 2R44GM110848-02 FY2015: $761,426 awarded for that fiscal year; activity R44 (SBIR); PI JARVIS, THALE CROSS; recipient as written: CRESTONE, INC., BOULDER, CO. Optimization and Lead Selection of Novel Antimy source ↗
2015 NIH contract (government contract; not a grant and not an investment round) 272201500012C-0-0-1 FY2015: $1,786,326 awarded for that fiscal year; activity N01 (OTHER_NIH); PI THALE, JARVIS; recipient as written: CRESTONE, INC., BOULDER, CO. Optimizing Lead Ther source ↗
Jul 25, 2014 NIH award 1R43GM110848-01 FY2014: $150,000 awarded for that fiscal year; activity R43 (SBIR); PI JARVIS, THALE CROSS; recipient as written: CRESTONE, INC., BOULDER, CO. Optimization and Lead Selection of Novel Antimy source ↗
Jul 3, 2014 NIH award 5R44AI090719-05 FY2014: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI JARVIS, THALE CROSS; recipient as written: CRESTONE, INC., BOULDER, CO. Development of a Novel PolC Inhibitor as a Gr source ↗
Jun 25, 2013 NIH award 5R44AI090719-04 FY2013: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI JARVIS, THALE CROSS; recipient as written: CRESTONE, INC., BOULDER, CO. Development of a Novel PolC Inhibitor as a Gr source ↗
Jun 13, 2012 NIH award 2R44AI090719-03 FY2012: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI JARVIS, THALE CROSS; recipient as written: CRESTONE, INC., BOULDER, CO. Development of a Novel PolC Inhibitor as a Gr source ↗
Jul 5, 2011 NIH award 5R43AI090719-02 FY2011: $496,897 awarded for that fiscal year; activity R43 (SBIR); PI JARVIS, THALE CROSS; recipient as written: CRESTONE, INC., BOULDER, CO. Novel DNA Polymerase Inhibitors as Gram-Positiv source ↗
Jul 6, 2010 NIH award 1R43AI090719-01 FY2010: $495,012 awarded for that fiscal year; activity R43 (SBIR); PI JARVIS, THALE CROSS; recipient as written: CRESTONE, INC., BOULDER, CO. Novel DNA Polymerase Inhibitors as Gram-Positiv source ↗